Abstract 1677P
Background
Chemotherapy (CT) often triggers physical and emotional changes impacting patients' lives, including their sexuality. Addressing sexual health (SH) issues is crucial for comprehensive cancer care. The aim of our study was to identify SH and intimacy issues in the Tunisian context among men undergoing CT.
Methods
The study was a cross-sectional, anonymous questionnaire-based study, conducted between March and May 2024 including 80 male cancer patients undergoing CT. Urological cancer patients were excluded. SH was evaluated by the EORTC Quality of Life Questionnaire Sexual Health (QLQ SH-22), which includes assessments of sexual satisfaction, sexual pain, sexual activity, treatment and partner-related issues. A higher score represents a higher level of symptomatology.
Results
Median age was 59.5 years [32-73]. Sixty-six patients (83%) were married and 79% were sexually active before the diagnosis. Colon cancer was the most common primary cancer (44%), followed by lung (20%) and pancreas (14%). Tumors were non metastatic in 55% of cases. The importance of communication about SH between doctors and patients was highlighted by 69% of respondents especially in those under 50 years old (95%). However, 59% considered it insufficient during checkups. The most commonly reported reason, cited by over half of patients (53%), was a lack of initiative on the part of physicians. Fifty-four patients (68%) expressed the importance of maintaining sexual activity. Yet only 33 (41%) remained sexually active during CT. Decreased libido was reported by 49 (61%) patients. Fifty-eight (73%) patients perceived a negative impact of CT on their SH. Forty-seven patients (59%) expressed dissatisfaction with communication about SH with their partners. The median sexual satisfaction score was 36 [3-60], with no correlation observed with socioeconomic status (p=0.89), educational level (p=0.09) or site of cancer (p=0.12). It was significantly higher among unmarried patients (OR=5.42, p=0.027) and in those with metastatic disease (OR=3.26, p=0.012).
Conclusions
The diagnosis and treatment of cancer significantly affect SH. Thus, providing sexual counseling to patients, especially in Arab countries where cancer and sexuality remain taboo, is essential to effectively meet their needs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1699P - Impact of Latino ethnicity on the gut microbiome and response to immune checkpoint inhibition (ICI) with CBM588 in patients (pts) with metastatic renal cell cancer (mRCC)
Presenter: Regina Barragan-Carrillo
Session: Poster session 11
1700P - Impact of sarcomatoid (S) and rhabdoid (R) components (comp.) on the efficacy of nivolumab (N) +/- ipilimumab (I) in the first-line (L1) treatment of metastatic clear cell renal cell carcinoma (mRCC) in the randomized phase II BIONIKK trial
Presenter: Yann-Alexandre Vano
Session: Poster session 11
1701P - NEOTAX: A phase II trial of neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus
Presenter: Liangyou Gu
Session: Poster session 11
1702P - Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh)
Presenter: Bradley McGregor
Session: Poster session 11
1703P - Updated overall survival in patients with prior checkpoint inhibitor (CPI) therapy in the phase III TIVO-3 study
Presenter: Miguel Zugman
Session: Poster session 11
1704P - Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study
Presenter: Renee Saliby
Session: Poster session 11
1705P - Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens
Presenter: Rashad Nawfal
Session: Poster session 11
1707P - A plasma proteomic based algorithm is associated with prognosis in renal cell carcinoma
Presenter: Eddy Saad
Session: Poster session 11
1708P - The clinical value of tumor-informed minimal residual disease detection in renal cell carcinoma
Presenter: linhui wang
Session: Poster session 11